Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16883674 | 0.83 | HSD17B10 (0.51) | OPRM1OPRL1CDK8CDK19HSD17B10 | |
| SCHEMBL13563372 | 0.83 | CDK8 (0.40) | SLC6A9OPRM1OPRL1CDK8CDK19 | |
| SCHEMBL14367298 | 0.80 | CDK8 (0.41) | SLC6A9OPRM1OPRL1CDK8CDK19 | |
| SCHEMBL4838402 | 0.78 | HSD17B10 (0.35) | CDK8CDK19HSD17B10 | |
| SCHEMBL12918587 | 0.78 | HSD17B10 (0.35) | CDK8CDK19HSD17B10 | |
| SCHEMBL24740359 | 0.78 | GRIN1 (0.38) | SLC6A9OPRM1OPRL1HSD17B10 | |
| SCHEMBL13541903 | 0.77 | OPRM1 (0.45) | OPRM1OPRL1CDK8CDK19OPRD1 | |
| SCHEMBL16750986 | 0.75 | GRIN1 (0.36) | SLC6A9OPRM1OPRL1HSD17B10 | |
| SCHEMBL16751010 | 0.75 | GRIN1 (0.38) | SLC6A9OPRM1OPRL1HSD17B10 | |
| SCHEMBL12028851 | 0.72 | SLC6A9 (0.34) | SLC6A9OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2732818-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS | LIGAND PHARM INC (US) | 2017-05-03 | — | — | EP | disclosed |